{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:49:24Z","timestamp":1783648164820,"version":"3.55.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00259-025-07212-3","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T08:15:17Z","timestamp":1743840917000},"page":"3682-3689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neuroendocrine peritoneal disease and [177Lu]DOTATATE peptide receptor radionuclide therapy: a therapeutic challenge with potential clinical complications"],"prefix":"10.1007","volume":"52","author":[{"given":"Nathan","family":"Poterszman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Baltzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darejan","family":"Mamulashvili Bessac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Pham Van","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Goichot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Mertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Brigand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-5146","authenticated-orcid":false,"given":"Alessio","family":"Imperiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"7212_CR1","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2967\/jnumed.123.266063","volume":"65","author":"L Al Mansour","year":"2024","unstructured":"Al Mansour L, De Mestier L, Haissaguerre M, Afchain P, Hadoux J, Lecomte T, et al. Outcome on mesenteric mass response of Small-Intestinal neuroendocrine tumors treated by 177Lu-DOTATATE peptide receptor radionuclide therapy: the mesenluth study, a National study from the French group of endocrine tumors and Endocan-RENATEN network. J Nucl Med. 2024;65:258\u201363.","journal-title":"J Nucl Med"},{"key":"7212_CR2","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1245\/s10434-016-5734-x","volume":"24","author":"A Madani","year":"2017","unstructured":"Madani A, Thomassen I, van Gestel YRBM, van der Bilt JDW, Haak HR, de Hingh IHJT, et al. Peritoneal metastases from gastroenteropancreatic neuroendocrine tumors: incidence, risk factors and prognosis. Ann Surg Oncol. 2017;24:2199\u2013205.","journal-title":"Ann Surg Oncol"},{"key":"7212_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1159\/000503144","volume":"110","author":"E Merola","year":"2020","unstructured":"Merola E, Prasad V, Pascher A, Pape U-F, Arsenic R, Denecke T, et al. Peritoneal carcinomatosis in Gastro-Entero-Pancreatic neuroendocrine neoplasms: clinical impact and effectiveness of the available therapeutic options. Neuroendocrinology. 2020;110:517\u201324.","journal-title":"Neuroendocrinology"},{"key":"7212_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2967\/jnumed.120.242875","volume":"62","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Al-Toubah T, Pell\u00e8 E, Smith J, Haider M, Hutchinson T, et al. Risk of bowel obstruction in patients with mesenteric or peritoneal disease receiving peptide receptor radionuclide therapy. J Nucl Med. 2021;62:69\u201372.","journal-title":"J Nucl Med"},{"key":"7212_CR5","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.2967\/jnumed.121.262048","volume":"62","author":"CE Wee","year":"2021","unstructured":"Wee CE, Dundar A, Eiring RA, Badawy M, Hobday TJ, Kendi AT, et al. Bowel obstruction as a complication of peptide receptor radionuclide therapy. J Nucl Med. 2021;62:1320.","journal-title":"J Nucl Med"},{"key":"7212_CR6","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2967\/jnumed.121.262782","volume":"63","author":"RP Reddy","year":"2022","unstructured":"Reddy RP, Ross Schmidtlein C, Giancipoli RG, Mauguen A, LaFontaine D, Schoder H, et al. The quest for an accurate functional tumor volume with 68Ga-DOTATATE PET\/CT. J Nucl Med. 2022;63:1027\u201332.","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"7212_CR7","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):S122\u201350.","journal-title":"J Nucl Med"},{"key":"7212_CR8","doi-asserted-by":"publisher","first-page":"e12936","DOI":"10.1111\/jne.12936","volume":"33","author":"E Pelle","year":"2021","unstructured":"Pelle E, Al-Toubah T, Morse B, El-Haddad G, Strosberg J. Desmoplastic mesenteric lesions do not respond radiographically to peptide receptor radionuclide therapy. J Neuroendocrinol. 2021;33:e12936.","journal-title":"J Neuroendocrinol"},{"key":"7212_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3390\/cancers13030443","volume":"13","author":"A Bla\u017eevi\u0107","year":"2021","unstructured":"Bla\u017eevi\u0107 A, Brabander T, Zandee WT, Hofland J, Franssen GJH, van Velthuysen M-LF, et al. Evolution of the mesenteric mass in small intestinal neuroendocrine tumours. Cancers (Basel). 2021;13:443.","journal-title":"Cancers (Basel)"},{"key":"7212_CR10","doi-asserted-by":"crossref","unstructured":"Laudicella R, Albano D, Bauckneht M, Urso L, Bodei L, De Rimini ML et al. Italian association of nuclear medicine, molecular imaging and therapy (AIMN) practical guide for peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-Oxodotreotide in gastroenteropancreatic neuroendocrine tumors (GEP-NET). Clin Transl Imaging. 2025.","DOI":"10.1007\/s40336-025-00679-y"},{"key":"7212_CR11","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.3390\/jcm9072203","volume":"9","author":"MI Del Olmo-Garc\u00eda","year":"2020","unstructured":"Del Olmo-Garc\u00eda MI, Muros MA, L\u00f3pez-de-la-Torre M, Agudelo M, Bello P, Soriano JM, et al. Prevention and management of hormonal crisis during theragnosis with LU-DOTA-TATE in neuroendocrine tumors. A systematic review and approach proposal. J Clin Med. 2020;9:2203.","journal-title":"J Clin Med"},{"key":"7212_CR12","doi-asserted-by":"publisher","first-page":"e222148","DOI":"10.1148\/radiol.222148","volume":"308","author":"A Gafita","year":"2023","unstructured":"Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, et al. Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic Castration-resistant prostate cancer. Radiology. 2023;308:e222148.","journal-title":"Radiology"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07212-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07212-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07212-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:58:49Z","timestamp":1757149129000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07212-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7212"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07212-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinky and was approved by the ICANS Review Board (IRB-2024-27).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a0.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}